A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Peripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile anddoi:10.4137/cmt.s3778 fatcat:ipftrlwtobfbnkt2qtey623zsi